Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ahmet Sevindik
Even though the Turkish government has settled some of the sizeable debt owed by hospitals to medical device and pharmaceutical suppliers, industry continues to be disgruntled over not being remunerated for the full amount owed and there continues to be wrangling over how the situation should be resolved.
The Turkish government is preparing to put a significant contract for the supply of tens of thousands of advanced imaging and monitoring devices up for grabs; medtech multinationals are teaming up with local manufacturing heavyweights to increase their chances of winning this tender.
Turkey will found a venture capital fund to acquire promising pharmaceutical start-ups and to support Turkish researchers in the US. The initiative comes from the industry, with support from the Turkish government. It is expected to gather pace after the elections on June 24.
Turkish interventional cardiology solutions firm Alvimedica is set to expand significantly its manufacturing capacity in a bid to further strengthen its position in the global heart stents and valves sectors. The company has ring-fenced around $370m to build a new facility, and its investment will be further supported by incentives from the Turkish government.
Turkey's TRPharm, in partnership with India's Dr Reddy's, has become the first company to gain a license for an oncology biosimilar Mab product in Turkey. Chairman Mehmet Göker spoke to Scrip about the company's international expansion plans.
Turkey's financially beleaguered university hospitals can finally breathe a sigh of relief after the Turkish government has agreed to step in to help pay off most – not all – of the billion-dollar debt owed to the medtech industry.